| Literature DB >> 21835052 |
Bogusz Trojanowicz1, Henning Dralle, Cuong Hoang-Vu.
Abstract
RNA-binding proteins may regulate every aspect of RNA metabolism, including pre-mRNA splicing, mRNA trafficking, stability and translation of many genes. The dynamic association of these proteins with RNA defines the lifetime, cellular localization, processing and the rate at which a specific mRNA is translated. One of the pathways involved in regulating of mRNA stability is mediated by adenylate uridylate-rich element (ARE) binding proteins. These proteins are involved in processes of apoptosis, tumorigenesis and development. Out of many ARE-binding proteins, two of them AUF1 and HuR were studied most extensively and reported to regulate the mRNA stability in vivo. Our previously published data demonstrate that both proteins are involved in thyroid carcinogenesis. Several other reports postulate that mRNA binding proteins may participate in thyroid hormone actions. However, until now, exacts mechanisms and the possible role of post-transcriptional regulation and especially the role of AUF1 and HuR in those processes remain not fully understood. In this study we shortly review the possible function of both proteins in relation to development and various physiological and pathophysiological processes, including thyroid function and disorders.Entities:
Year: 2011 PMID: 21835052 PMCID: PMC3155111 DOI: 10.1186/1756-6614-4-S1-S5
Source DB: PubMed Journal: Thyroid Res ISSN: 1756-6614
ARE-containing mRNAs related to thyroid function, development and disorders. According to AREsite http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi.
| ARE-motifs | |||||
|---|---|---|---|---|---|
| mRNA | AUUUA | WTAUUUATW | WWWWAUUUAWWWW | WWAUUUAWW | Others |
| Selenoproten P | 6 | 1 | 1 | 2 | |
| MCT8 | 5 | ||||
| ID2 | 3 | 1 | 1 | 1 | 1 |
| Pendrin | 6 | 2 | 1 | 2 | 4 |
| THR alpha | 2 | 1 | |||
| THR beta | 14 | 1 | 2 | ||
| Thyroid adenoma associated protein | 18 | 1 | 2 | 6 | 6 |
| TTF-1 (Nkx2-1) | 6 | 3 | 2 | 4 | 4 |
| TSH-R | 2 | ||||
| TPO | 3 | 2 | |||
| THR associated protein 6 | 2 | 1 | |||
| Papillary thyroid carcinoma encoded protein | 10 | 2 | 1 | 3 | 2 |
| Dual oxidase 1 | 1 | ||||
| Thyroid cancer protein | 5 | 1 | 1 | 2 | 2 |
| PAX8 | 3 | 1 | 2 | 3 | |
| NIS | 1 | ||||
| D1 | 3 | ||||
| Homebox protein HEX (HHEX) | 2 | ||||
| Eyes absent homolog EYA1 | 5 | 2 | 1 | ||
| Homebox protein Hox-A3 | 7 | 1 | 1 | 1 | 3 |
| Homebox protein Hox-A5 | 1 | 1 | 1 | ||
| PAX9 | 4 | 1 | 3 | ||
| Peroxiredoxin 6 (PRDX6) | 2 | ||||
| Peroxiredoxin 3 (PRDX3) | 1 | ||||
| Peroxiredoxin 4 (PRDX4) | 1 | ||||
Thyroid developmental markers containing ARE-sequences and phenotypes studied on double knock-out mice, modified from [85].
| Double knock-out | Thyroid phenotype |
|---|---|
| Pax8 -/- | Regression of thyroid primordium at E11.5 |
| Pax9 -/- | Lack of ultimobranchial body formation |
| Ttif1/Nkx2.1 -/- | Thyroid precursor cells disappear at E10.5-11.5; |
| Hhex -/- | Thyroid anlage present at E9; |
| Eya1 -/- | lack of fusion between ultimobranchial bodies and thyroid lobes; thyroid hypoplasia; severe reduction in number of C-cells and follicular cells; |
| Hoxa3 -/- | Thyroid hypoplasia; persistent ultimobranchial bodies with C-cells |
| Hoxa5 -/- | Disorganized follicle formation; decreased TPO; Nkx2.1, Titf2, Pax8 gene expression altered, but normal serum T4 level |
Figure 1Upper panel: expression of CD82 in thyroid carcinoma cell lines treated with siRNA targeting AUF1. Lower panel: expression of CD9, CD82, GAPDH, ENO1 and S100A4 in wild type cells FTC-133, FTC-133-EGFP control cells (E19) and FTC-133 transfectants expressing AUF1 targeting shRNAs (A13, A17, A21). Increased levels of tumor suppressors (CD9 and CD82) and subsequent decrease of tumor promoters (ENO1, GAPDH and S100A4) are visible. Note that 8505C control and AUF1-siRNA cells are CD82 negative. 18S and B-actin served as normalizing markers.
Figure 2Expression of AUF1 and HuR after RA pre-treatment and ENO1-siRNA employment. Upper panel: FTC-133 cells pre-treated with RA revealed decreased levels of AUF1 and HuR. Lower panel: ENO1 knock-down led to decreased levels of AUF1 and HuR. B-actin served as normalizing marker.